Document is current
Any future updates will be listed below
-
Authors
Hanna, Sandra https://orcid.org/0009-0005-1337-3310
Faiz, Mark
Ahmed, Sanjida https://orcid.org/0000-0002-9377-1933
Hsieh, Cindy
Temkit, Sara
Nunez, Cristina
Zhou, Feng
- License Information
-
More Information
Article History
Received: 11 September 2023
Revised: 31 March 2025
Accepted: 15 April 2025
First Online: 7 May 2025
Competing interests
: The authors listed below declare that they are employed by PPI, the company that conducted this study. However, this study was not funded by any external sources and included strictly the use of secondary data.
: All methods followed relevant ethical guidelines and regulations. The study was approved by the Veritas IRB, Montreal, Quebec (reference number 2023-3293-14986-2), for the human studies involved. Informed consent was obtained from participants voluntarily seeking commercial pharmacogenomic testing, with consent to use their data in aggregated form for research. However, under Article 2.5 of the Tri-Council Policy Statement 2, this analysis qualifies as a research study not requiring additional informed consent, due to the secondary use of non-identifiable data collected for commercial purposes.
